Neurogene Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
131
- Stock Symbol
-
NGNE
- Investments
-
1
- Share Price
-
$23.88
- (As of Thursday Closing)
Neurogene General Information
Description
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Contact Information
Website
www.neurogene.comCorporate Office
- 535 West 24th Street
- 5th Floor
- New York, NY 10011
- United States
Corporate Office
- 535 West 24th Street
- 5th Floor
- New York, NY 10011
- United States
Neurogene Timeline
Neurogene Stock Performance
As of 12-Nov-2026, Neurogene’s stock price is $23.88. Its current market cap is $495M with 20.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $23.88 | $25.10 | $15.93 - $43.66 | $495M | 20.7M | 306K | -$5.03 |
Neurogene Financials Summary
As of 30-Sep-2026, Neurogene has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 340,077 | 64,953 | 215,119 | 451,539 |
| Revenue | 0 | 0 | 925 | 0 |
| EBITDA | (126,112) | (98,801) | (80,352) | (35,921) |
| Net Income | (119,180) | (90,351) | (75,144) | (36,317) |
| Total Assets | 377,901 | 288,604 | 335,730 | 222,573 |
| Total Debt | 7,953 | 10,957 | 14,237 | 16,255 |
Neurogene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neurogene Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Neurogene Comparisons
Industry
Financing
Details
Neurogene Competitors (25)
One of Neurogene’s 25 competitors is CuraSen, a Venture Capital-Backed company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Minerva Neurosciences | Formerly VC-backed | Burlington, MA | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY |
Neurogene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neurogene Patents
Neurogene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2025525430-A | Neo-2/15 variants and their uses for preferentially stimulating t regulatory cells - patents.com | Pending | 01-Jul-2022 | ||
| AU-2023298151-A1 | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells | Pending | 01-Jul-2022 | ||
| EP-4547698-A1 | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells | Pending | 01-Jul-2022 | ||
| US-20250361308-A1 | Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells | Pending | 01-Jul-2022 | ||
| WO-2023114816-A1 | Recombinant optimized galc constructs and methods for treating galc-associated disorders | Inactive | 14-Dec-2021 | C07K14/475 |
Neurogene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neurogene Acquisitions (1)
Neurogene’s most recent deal was a Merger/Acquisition with Neoleukin Therapeutics. The deal was made on 18-Dec-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Neoleukin Therapeutics | 18-Dec-2023 | Merger/Acquisition | Drug Discovery |
Neurogene ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Neurogene FAQs
-
When was Neurogene founded?
Neurogene was founded in 2018.
-
Where is Neurogene headquartered?
Neurogene is headquartered in New York, NY.
-
What is the size of Neurogene?
Neurogene has 131 total employees.
-
What industry is Neurogene in?
Neurogene’s primary industry is Drug Discovery.
-
Is Neurogene a private or public company?
Neurogene is a Public company.
-
What is Neurogene’s stock symbol?
The ticker symbol for Neurogene is NGNE.
-
What is the current stock price of Neurogene?
As of 12-Nov-2026 the stock price of Neurogene is $23.88.
-
What is the current market cap of Neurogene?
The current market capitalization of Neurogene is $495M.
-
Who are Neurogene’s competitors?
CuraSen, Alzheon, Minerva Neurosciences, Alector, and Cognition Therapeutics are some of the 25 competitors of Neurogene.
-
What is Neurogene’s annual earnings per share (EPS)?
Neurogene’s EPS for 12 months was -$5.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
